A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma

OBJECTIVES: The Kirsten Rat Sarcoma (KRAS) mutation is the commonest oncogenic drive mutation in lung adenocarcinoma (LUAD) and immunotherapy may be quite promising for KRAS-mutant LUAD. While the effects of tumor mutation burden (TMB) and copy number alteration (CNA) are poorly understood in this i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Luochengling, Fu, Xiao, Wang, Xiao, Li, Wenyuan, Zheng, Xiaoqiang, Nan, Kejun, Tian, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541961/
https://www.ncbi.nlm.nih.gov/pubmed/33072585
http://dx.doi.org/10.3389/fonc.2020.559896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541961/
https://www.ncbi.nlm.nih.gov/pubmed/33072585
http://dx.doi.org/10.3389/fonc.2020.559896

Ejemplares similares